Compare HYNE & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HYNE | ANIX |
|---|---|---|
| Founded | 2025 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.6M | 114.0M |
| IPO Year | 2025 | 2013 |
| Metric | HYNE | ANIX |
|---|---|---|
| Price | $17.51 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 8.0K | ★ 229.4K |
| Earning Date | 11-08-2026 | 09-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.56 | $2.32 |
| 52 Week High | $17.26 | $5.46 |
| Indicator | HYNE | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 83.29 | 43.58 |
| Support Level | $16.31 | $2.62 |
| Resistance Level | N/A | $3.09 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 74.63 | 21.57 |
Hoyne Bancorp Inc is a holding company that conducts business mainly through its subsidiaries. It is a savings institution focused on serving customers' banking needs in the market area. The group offers Personal and Business banking services.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.